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Medical Center, Dallas, TX, USARenal insufﬁciency is common in patients with end-stage liver
disease (ESLD) and is strongly linked to survival in those awaiting
liver transplantation. In liver patients, renal dysfunction is largely
due to a circulatory disturbance characterized by a low systemic
vascular resistance and decreased effective arterial volume lead-
ing to impaired renal excretion of solute-free water, dilutional
hyponatremia and ultimately hepatorenal syndrome (HRS) [1–
3]. Once a patient develops type I HRS, the median survival with-
out treatment is as low as 2 weeks, while the median survival in
type II HRS is approximately six months; both a signiﬁcant
decrease in survival compared to patients without HRS [1,4,5].
The diagnosis and severity of HRS is dependent on two biochem-
ical markers, serum sodium and creatinine, both of which are
independently associated with an increased risk of mortality in
cirrhosis [6–14]. Their importance is underscored by inclusion
in the most widely utilized predictive survival function, the
model for end-stage liver disease (MELD) score or Na-MELD,
where the addition of serum sodium signiﬁcantly improves [9–
14] the performance of MELD. Whether sodium will be included
into the MELD score (for prioritizing liver transplantation candi-
dates) remains in question for two reasons. Serum sodium levels
are easily manipulated with water ingestion and the administra-
tion of vaptans. In addition, hyponatremia may have a negative
impact on post-transplant complications and survival, [15–17]
although recent data have brought this into question [18].
While serum sodiumand creatinine are important predictors of
mortality in cirrhosis, their relationship to themost sensitivegauge
of renal function, measured glomerular ﬁltration rate (GFR), is
more complicated. To the degree that renal handling of sodium
and water is altered in cirrhosis, serum sodium is determined by
renal function. However, serum sodium only correlates roughly
with GFR.With regard to serum creatinine, numerous studies have
documented its incongruity with measured as well as estimated
GFR. Speciﬁcally, creatinine typically overestimates renal function
in patients listed for liver transplantation [19,20], particularly in
those with the lowest GFR. This discrepancy may be due to lowerJournal of Hepatology 20
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E-mail address: james.trotter@baylorhealth.edu (J.F. Trotter).serum creatinine levels in liver patients caused by decreased
hepatic creatine production, poor nutrition, decreased muscle
mass, and increased tubular secretion of creatinine [21,22]. Fur-
thermore, in jaundiced patients, elevated bilirubin levels may
interfere with commonly used assays leading to further variability
in serum creatinine and MELD scores [22].
With this background Lim et al. have addressed the following
issue: while renal disease and its serum markers, i.e., serum
sodium and creatinine, are important predictors for survival in
cirrhosis, their correlation with the gold-standard of renal func-
tion, measured GFR, is poor. Therefore, could the predictive
capacity of the MELD score be improved by replacement of creat-
inine (and sodium) with measured GFR? This is a clever analysis
which could only be conducted in very few places, because only a
small number of liver transplant programs routinely measure
GFR with iothalamate (or similar methodology) in their liver
transplant candidates. Its rarity is likely due to the cumbersome
nature of the test, requiring pre-test hydration and careful collec-
tion of timed samples over several hours after iothalamate
administration. Consequently, GFR is usually measured only once
during the evaluation phase of transplant candidacy and is poorly
suited for critically ill or hospitalized patients. Lim et al. analyzed
the effect of the measured GFR on the predictive capacity of
MELD and we learn several key points from their study. First,
there was an association between one-year mortality and mea-
sured renal function. While this is not a surprise to experienced
clinicians, the strength of the association is remarkable. The
one-year mortality rates for patients with a measured GFR of
30–60 ml/min and <30 ml/min were more than threefold and
ﬁvefold higher, respectively, compared to patients with normal
renal function (GFR > 60 ml/min). In fact, GFR had a signiﬁcant
linear association with survival, independent of MELD score. Sec-
ond, measured GFR was superior to serum creatinine as a predic-
tor of mortality, in a model incorporating bilirubin, INR, and GFR
(in the place of serum creatinine). Finally, the effect of serum
sodium on the model loses signiﬁcance when GFR is included.
Thus, inclusion of sodium in the MELD score may not be neces-
sary if measured GFR (or perhaps a yet-to-be-determined mar-
ker) is used to determine renal function.
There are some qualiﬁcations to the ﬁndings in this study. The
cohort is derived from the pre-MELD era. Consequently, the
analyzed patients are likely to be less sick (median serum
creatinine = 1.0 mg/dl and serum sodium 137 mEq/L) and have
different demographics (only 20% with hepatitis C) than current10 vol. 52 j 622–623
JOURNAL OF HEPATOLOGY
liver transplant recipients. In addition, the total waiting list
mortality (9.2%) over the course of this multi-year study was
quite low, compared to current standards. These differences
might limit the applicability of the authors’ ﬁndings in our cur-
rent cohort of liver transplant candidates. Finally, the improve-
ment reported by the authors, while statistically signiﬁcant, is
relatively small between MELD (C-statistic = 0.780) and MELD
with GFR (C-statistic = 0.792).
Overall, the authors have broadened our understanding of the
impact of renal function, and its markers, on the MELD score.
Modiﬁcation of the MELD score to include measured GFR may
indeed improve the predictive accuracy of the model, yet chal-
lenges arise in its general applicability. Serum creatinine and
serum sodium are easily accessible to all clinicians evaluating
liver transplant candidates. In contrast, methods to assess GFR,
including clearance of compounds such as iothalamate, require
specialized laboratory resources not readily available at all liver
transplant centers. However, these ﬁndings suggest that identiﬁ-
cation of more accurate laboratory tests for renal function might
improve the predictive function of the MELD score. Perhaps the
most likely candidate for this role is serum cystatin C. Unfortu-
nately, there is relatively little data available assessing this mar-
ker in cirrhotic patients. Nevertheless, the available data suggests
that, compared to serum creatinine, cystatin might provide a
slightly more accurate estimate of renal function and therefore
could improve the predictive capacity of the MELD [23–27].
Whether this or any other marker could improve the function
of MELD will require further careful analysis.
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